Acadian Asset Management
ALDX icon

Acadian Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Acadian Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
1,063,793
+205,505
+24% +$353K ﹤0.01% 1047
2026
Q1 		$1.45M Sell
858,288
-121,233
-12% -$531K ﹤0.01% 1048
2025
Q4 		$5.07M Buy
979,521
+143,710
+17% +$738K 0.01% 649
2025
Q3 		$4.36M Buy
835,811
+643,409
+334% +$3.36M 0.01% 679
2025
Q2 		$735K Buy
192,402
+96,442
+101% +$249K ﹤0.01% 1054
2025
Q1 		$551K Buy
95,960
+94,681
+7,403% +$560K ﹤0.01% 1061
2024
Q4 		$6K Sell
1,279
-253,035
-99% -$1.3M ﹤0.01% 1568
2024
Q3 		$1.37M Sell
254,314
-191,572
-43% -$912K ﹤0.01% 853
2024
Q2 		$1.48M Sell
445,886
-6,563
-1% -$25.7K ﹤0.01% 869
2024
Q1 		$1.48M Buy
452,449
+233,169
+106% +$767K 0.01% 743
2023
Q4 		$768K Buy
+219,280
New +$677K ﹤0.01% 931
2021
Q1 		– Sell
-33,986
Closed -$233K – 2039
2020
Q4 		$233K Buy
+33,986
New +$239K ﹤0.01% 1496
2020
Q3 		– Sell
-159,445
Closed -$665K – 2152
2020
Q2 		$665K Buy
159,445
+126,347
+382% +$462K ﹤0.01% 1097
2020
Q1 		$82K Buy
33,098
+28,079
+559% +$126K ﹤0.01% 1390
2019
Q4 		$29K Buy
+5,019
New +$29K ﹤0.01% 1679
2019
Q2 		– Sell
-16,044
Closed -$145K – 1746
2019
Q1 		$145K Buy
+16,044
New +$136K ﹤0.01% 1430
2018
Q3 		– Sell
-13,833
Closed -$110K – 1650
2018
Q2 		$110K Buy
13,833
+5,915
+75% +$47.2K ﹤0.01% 1216
2018
Q1 		$59K Buy
7,918
+2,384
+43% +$18.1K ﹤0.01% 1331
2017
Q4 		$38K Buy
+5,534
New +$36.5K ﹤0.01% 1267

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management's ALDX Position: Q2 2026 in Review

Acadian Asset Management increased its Aldeyra Therapeutics (ALDX) stake by 24% in Q2 2026, buying an estimated $353K and bringing the position to 1,063,793 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

Acadian Asset Management first reported a position in ALDX in Q4 2017 and has held it in 19 quarters since. The position peaked at $5.07M in Q4 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Acadian Asset Management held 1,063,793 shares of Aldeyra Therapeutics worth $2.26M as of Q2 2026.
  • Acadian Asset Management bought 205,505 Aldeyra Therapeutics shares in Q2 2026, an estimated $353K.
  • Aldeyra Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1047 holding.
  • Acadian Asset Management first reported a position in Aldeyra Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • Acadian Asset Management's Aldeyra Therapeutics position peaked at $5.07M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.